See more : Robex Resources Inc. (RBX.V) Income Statement Analysis – Financial Results
Complete financial analysis of Burning Rock Biotech Limited (BNR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Burning Rock Biotech Limited, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Umami Sustainable Seafood Inc. (UMAM) Income Statement Analysis – Financial Results
- Sdiptech AB (publ) (SDIP-B.ST) Income Statement Analysis – Financial Results
- Saturn Oil & Gas Inc. (SOIL.TO) Income Statement Analysis – Financial Results
- XPON Technologies Group Limited (XPN.AX) Income Statement Analysis – Financial Results
- Norstar Holdings Inc. (NSTR.TA) Income Statement Analysis – Financial Results
Burning Rock Biotech Limited (BNR)
About Burning Rock Biotech Limited
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based cancer therapy selection and prognosis prediction tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. In addition, the company has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. It has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. The company was incorporated in 2014 and is headquartered in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 537.44M | 563.24M | 507.86M | 429.90M | 381.68M | 208.87M | 111.17M |
| Cost of Revenue | 174.21M | 183.20M | 143.72M | 115.98M | 108.34M | 73.81M | 39.47M |
| Gross Profit | 363.23M | 380.04M | 364.15M | 313.92M | 273.33M | 135.06M | 71.70M |
| Gross Profit Ratio | 67.59% | 67.47% | 71.70% | 73.02% | 71.61% | 64.66% | 64.49% |
| Research & Development | 347.02M | 421.87M | 367.86M | 263.94M | 156.94M | 105.30M | 49.02M |
| General & Administrative | 437.82M | 568.28M | 490.26M | 293.80M | 132.16M | 88.30M | 76.04M |
| Selling & Marketing | 247.71M | 370.29M | 303.10M | 168.59M | 153.33M | 102.86M | 67.51M |
| SG&A | 685.53M | 938.58M | 793.35M | 462.39M | 285.49M | 191.16M | 143.54M |
| Other Expenses | 0.00 | 152.00K | 199.00K | -887.00K | -883.00K | -488.00K | -32.00K |
| Operating Expenses | 1.03B | 1.36B | 1.16B | 726.33M | 442.43M | 296.46M | 192.56M |
| Cost & Expenses | 1.21B | 1.54B | 1.30B | 842.31M | 550.77M | 370.26M | 232.03M |
| Interest Income | 17.96M | 9.46M | 3.46M | 6.07M | 2.17M | 1.34M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 1.54M | 667.00K | 8.99M | 17.95M | 0.00 |
| Depreciation & Amortization | 133.40M | 124.10M | 47.77M | 33.31M | 31.36M | 24.68M | 21.31M |
| EBITDA | -537.87M | -856.31M | -746.50M | -373.26M | -136.38M | -135.87M | -99.55M |
| EBITDA Ratio | -100.08% | -174.34% | -156.23% | -94.72% | -35.73% | -65.05% | -89.09% |
| Operating Income | -669.32M | -980.41M | -797.06M | -412.41M | -169.09M | -161.40M | -120.87M |
| Operating Income Ratio | -124.54% | -174.07% | -156.94% | -95.93% | -44.30% | -77.27% | -108.73% |
| Total Other Income/Expenses | 18.02M | 11.16M | 1.27M | 5.17M | -64.00K | -16.10M | -10.41M |
| Income Before Tax | -651.30M | -969.25M | -795.80M | -407.24M | -169.16M | -177.50M | -131.28M |
| Income Before Tax Ratio | -121.19% | -172.08% | -156.70% | -94.73% | -44.32% | -84.98% | -118.09% |
| Income Tax Expense | 2.39M | 1.99M | 899.00K | -33.53M | -819.00K | 1.85M | 10.38M |
| Net Income | -653.69M | -971.23M | -796.70M | -373.71M | -168.34M | -177.50M | -131.28M |
| Net Income Ratio | -121.63% | -172.44% | -156.87% | -86.93% | -44.10% | -84.98% | -118.09% |
| EPS | -63.84 | -9.35 | -7.65 | -5.44 | -1.94 | -7.93 | -1.60 |
| EPS Diluted | -63.84 | -9.35 | -7.65 | -5.44 | -1.94 | -7.93 | -1.60 |
| Weighted Avg Shares Out | 10.24M | 103.91M | 104.21M | 68.63M | 86.82M | 22.38M | 82.08M |
| Weighted Avg Shares Out (Dil) | 10.24M | 103.91M | 104.21M | 68.63M | 86.82M | 22.38M | 82.08M |
Burning Rock Announces the Launch of China's First Prospective Pan-Cancer Multi-omics Early Detection Study
Burning Rock to be Added to MSCI China Index
Burning Rock Schedules First Quarter of 2021 Earnings Release on May 25, 2021
Burning Rock's Liquid Biopsy Assay Achieved Strong Performance in the FDA-led SEQC2 Study, with Results Published on Nature Biotechnology
Burning Rock Biotech Limited (BNR) CEO Yusheng Han on Q4 2020 Results - Earnings Call Transcript
Burning Rock Reports Fourth Quarter and Full Year 2020 Financial Results
Burning Rock Announces Preliminary Fourth Quarter and Full Year 2020 Results and Schedules Earnings Release on March 11, 2021
Burning Rock (BNR) in Focus: Stock Moves 5.4% Higher
Burning Rock Biotech Expands Test Portfolio In Bid For Growth
OCX Stock: Why Shares of Biotech OncoCyte Are Skyrocketing Today
Source: https://incomestatements.info
Category: Stock Reports